School of Pharmacy and Biomolecular Sciences, The Royal College of Surgeons in Ireland, Dublin, Ireland.
FutureNeuro SFI Research Centre, Dublin, Ireland.
Eur J Hum Genet. 2020 Aug;28(8):1066-1077. doi: 10.1038/s41431-020-0610-3. Epub 2020 Apr 1.
Next generation sequencing provides an important opportunity for improved diagnosis in epilepsy. To date, the majority of diagnostic genetic testing is conducted in the paediatric arena, while the utility of such testing is less well understood in adults with epilepsy. We conducted whole exome sequencing (WES) and copy number variant analyses in an Irish cohort of 101 people with epilepsy and co-morbid intellectual disability to compare the diagnostic yield of genomic testing between adult and paediatric patients. Variant interpretation followed American College of Medical Genetics and Genomics (ACMG) guidelines. We demonstrate that WES, in combination with array-comparative genomic hybridisation, provides a diagnostic rate of 27% in unrelated adult epilepsy patients and 42% in unrelated paediatric patients. We observe a 2.7% rate of ACMG-defined incidental findings. Our findings indicate that WES has similar utility in both adult and paediatric cohorts and is appropriate for diagnostic testing in both epilepsy patient groups.
下一代测序为改善癫痫症的诊断提供了重要机会。迄今为止,大多数诊断性基因检测都是在儿科领域进行的,而在癫痫合并智力障碍的成年患者中,这种检测的实用性还不太清楚。我们对 101 名患有癫痫和合并智力障碍的爱尔兰患者进行了全外显子组测序(WES)和拷贝数变异分析,以比较基因组检测在成年和儿科患者之间的诊断效果。变异解释遵循美国医学遗传学与基因组学学会(ACMG)指南。我们证明,WES 与阵列比较基因组杂交相结合,可提供 27%的无关成年癫痫患者和 42%的无关儿科患者的诊断率。我们观察到 ACMG 定义的偶然发现的发生率为 2.7%。我们的研究结果表明,WES 在成年和儿科患者中具有相似的效用,适用于这两个癫痫患者群体的诊断测试。